Neohesperidin Regulates Lipid Metabolism and Ameliorates MASLD by Targeting ECHS1
Phytotherapy Research · 2026
DOI: 10.1002/ptr.70400 ↗At a glance
Journal article in Phytotherapy Research, 2026. Written by Hongyan Zhu and 10 co-authors. Institution: Department of Clinical Pharmacy, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Major MEDLINE topics: Lipid Metabolism, Hesperidin, Non-alcoholic Fatty Liver Disease, Fatty Liver. 36 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Young Talent Project of the Chinese Pharmaceutical Association, Young Talent Capacity Improvement Plan of the Shanghai Pharmaceutical Association.
Abstract (original language)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a highly prevalent chronic liver condition globally, closely linked to disrupted lipid metabolism, yet effective targeted therapies remain elusive. While we previously reported the efficacy of ShuGan‐QieZhi Capsule against fatty liver disease, the therapeutic potential of its active component, Neohesperidin (NH), in MASLD was unknown. Here, we demonstrate that NH effectively alleviates lipid accumulation in high‐fat diet (HFD)‐induced mice and palmitic acid (PA)‐treated hepatocytes. Mechanistically, NH directly binds to PHE248 of ECHS1, a key enzyme in fatty acid β‐oxidation, and inhibits its ubiquitin‐proteasome‐mediated degradation, thereby stabilizing ECHS1 and promoting lipid catabolism. Additionally, NH modulates the PPARα signaling pathway, contributing to its overall therapeutic effect. Our findings not only identify ECHS1 as a promising therapeutic target for MASLD but also propose NH as a first‐in‐class small molecule that directly stabilizes ECHS1, providing a novel strategy against MASLD by targeting protein stability to restore lipid homeostasis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Pharmacy, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Center for Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
ORCID profiles: Min Yang, Xisong Ke, Jian Zhang
Funding
- National Natural Science Foundation of China
- Young Talent Project of the Chinese Pharmaceutical Association
- Young Talent Capacity Improvement Plan of the Shanghai Pharmaceutical Association
- Discipline Construction of Pudong Health Bureau of Shanghai-Discipline Group of Cerebrovascular System Diseases
Cite
APA
Zhu, H., Zhu, T., Yang, M., Huang, X., Gao, S., Li, M., Shu, Y., Yu, X., Ke, X., Zhang, J., & Qi, J. (2026). Neohesperidin Regulates Lipid Metabolism and Ameliorates MASLD by Targeting ECHS1. Phytotherapy Research. https://doi.org/10.1002/ptr.70400
Vancouver
Zhu H, Zhu T, Yang M, Huang X, Gao S, Li M, et al. Neohesperidin Regulates Lipid Metabolism and Ameliorates MASLD by Targeting ECHS1. Phytotherapy Research. 2026. doi:10.1002/ptr.70400
BibTeX
@article{Zhu2026,
author = {Zhu, Hongyan and Zhu, Tong and Yang, Min and Huang, Xiaohui and Gao, Shengwang and Li, Mingfei and Shu, Yang and Yu, Xinran and Ke, Xisong and Zhang, Jian and Qi, Jia},
title = {Neohesperidin Regulates Lipid Metabolism and Ameliorates MASLD by Targeting ECHS1},
journal = {Phytotherapy Research},
year = {2026},
doi = {10.1002/ptr.70400}
}
EUVIMED